No news is bad news for Atara

A much-hyped interim analysis for ATA188, Atara’s potentially remyelinating therapy for multiple sclerosis, has revealed... nothing much. Before the analysis the sellside had suggested that the outcome that came to pass – continuing the phase 2 portion of the Embold study without upping patient numbers – would be positive.